About us
- >
- About us >
- Information >
- Announcement
2025-03-17
Energenesis Biomedical and Medvisis Switzerland AG Sign MOU for F703DFU Commercialization in Switzerland
- Energenesis Biomedical has signed an MOU with Medvisis for the commercialization of F703DFU Diabetic Foot Ulcer Gel (F703DFU) in the Swiss market.
- Medvisis will provide consultation for the Phase III clinical trial of F703DFU in Europe.
- Medvisis will continue to support the Phase III clinical trials and commercialization of F703VLU (Venous Leg Ulcer Gel) and F701 (Topical Solution for Hair Loss Prevention) in Switzerland and the European market.